Navigation Links
Novartis begins shipment of seasonal influenza vaccines to US market
Date:8/21/2013

with Fluvirin and Flucelvax to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Fluvirin or Flucelvax will achieve any particular levels of revenue in the future. In particular, management's expectations regarding Fluvirin and Flucelvax could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; competition in general; government, industry and general public pricing pressures; unexpected manufacturing issues; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novart
'/>"/>

SOURCE Novartis
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Novartiss Serelaxin Has the Potential to Fulfill the Most Pertinent Unmet Needs in Acute Heart Failure by Reducing the Rate of Patient Mortality and the Rate of Worsening Renal Function
2. Novartis Breakthrough Therapy LDK378 shows a marked clinical response in patients with ALK+ non-small cell lung cancer
3. Novartis Pharmaceuticals Corporation disputes allegations in two US Government lawsuits and looks forward to a fair discussion of the facts
4. Novartis signs on to support Malaria No Mores Power of One campaign to stride towards a future without malaria
5. Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
6. Novartis Pharma Logistics, Inc. voluntarily recalling in Jamaica select lots of certain over-the-counter products due to bottle closure defect
7. Novartis Pharma Logistics, Inc. voluntarily recalling in Trinidad & Tobago select lots of certain over-the-counter products due to bottle closure defect
8. Novartis Pharma Logistics, Inc. voluntarily recalling in Curacao select lots of certain over-the-counter products due to bottle closure defect
9. Novartis Pharma Logistics, Inc. voluntarily recalling in Aruba select lots of certain over-the-counter products due to bottle closure defect
10. Novartis Pharma Logistics, Inc. voluntarily recalling in Barbados select lots of certain over-the-counter products due to bottle closure defect
11. Continued Uptake of Novartis/Incytes Jakafi Will Be the Greatest Driver of Growth in the Myelofibrosis Therapy Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014  Hologic, Inc. (NASDAQ: HOLX ), ... and Chief Executive Officer, will preside over the NASDAQ ... first day of Breast Cancer Awareness Month. In his ... on the important benefits of Hologic,s 3D Mammography technology, ... clinically superior to traditional mammography. This is ...
(Date:9/30/2014)... , Sept. 30, 2014 Arbor ... Summary Global Markets Direct,s, ,Arbor Pharmaceuticals, ... an overview of the Arbor Pharmaceuticals, LLC.,s pharmaceutical ... comprehensive information on the current therapeutic developmental pipeline ... at various stages, therapeutics assessment by drug target, ...
(Date:9/30/2014)... DALLAS , September 30, 2014 /PRNewswire/ ... market research report the "Glycobiology/Glycomics Market by Product ... Spectrometry, MALDI-TOF), Kits, and Reagents], Application (Immunology, ... Forecast to 2019", published by MarketsandMarkets, provides ... restraints, challenges, opportunities, current market trends, and ...
Breaking Medicine Technology:Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
(Date:10/1/2014)... 01, 2014 Two bicyclists began a ... across the country in an effort to raise funds ... The cyclists, a father-daughter team, plan to bike ... Blaine, Washington and finishing in Key West Florida. ... The Warriors®, a national nonprofit organization that assists post-9/11 ...
(Date:10/1/2014)... UP4 Probiotics will be donating a portion ... National Network to End Domestic Violence ( http://www.nnedv.org ) ... through nationwide polling that took place during August and ... , “We are proud to have been chosen by ... of UP4 Women’s Probiotics during the month of October,” ...
(Date:10/1/2014)... 2014 After a run of successful ... emerging filmmaker Jacqui Blue is continuing her mission to ... truth about natural birth. The documentary has received a ... world and has been an effective medium for starting ... highlighted in the film provide a wealth of information ...
(Date:10/1/2014)... Looking for holiday gift ideas? Éminence Organic ... gift giving easy this holiday season. Starting October 1st 2014, ... solve all shopping dilemmas. Choose from two luxury skin care ... the delicate eye area or to deliver whole body beauty. ... Rescue Duo Gift Set are formulated to suit all skin ...
(Date:10/1/2014)... VA (PRWEB) October 01, 2014 The annual ... levels again in 2015, says a new forecast by ... most recent consumer price index (CPI) data through August, TSCL ... “That would make the sixth consecutive year of record low ... the COLA first became automatic in 1975,” he notes. , ...
Breaking Medicine News(10 mins):Health News:Father-Daughter Cycling Duo to Ride Cross-Country to Benefit Hope For The Warriors 2Health News:UP4 Probiotics Partners with The National Network to End Domestic Violence 2Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 2Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 3Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 4Health News:Éminence Organic Skin Care Launches Limited Edition Spa Gift Sets for the Holiday Season 2Health News:Éminence Organic Skin Care Launches Limited Edition Spa Gift Sets for the Holiday Season 3Health News:The Senior Citizens League (TSCL) Says Sixth Consecutive Year Of Record Low COLAs “Unprecedented” 2Health News:The Senior Citizens League (TSCL) Says Sixth Consecutive Year Of Record Low COLAs “Unprecedented” 3
... Research (AADR) has announced Irwin D. Mandel, AADR past president ... of the inaugural 2010 AADR Distinguished Mentoring Award. This award ... in Washington, DC, March 3, 2010. Mandel began ... up his part-time private practice in 1968 to devote himself ...
... could lead to new treatments, study suggests , FRIDAY, Feb. ... for cystic fibrosis, U.S. researchers have identified a defective signaling ... disease. , Cystic fibrosis causes thick, sticky mucus to build ... of the most common potentially lethal genetic diseases in children ...
... ... ... ... ...
... ... ... the release of the 2010 U.S. Ambulatory EHR Study, a strategic analysis of the U.S. ... (HITECH) component of the American Recovery and Reinvestment (ARRA) Act. ,As recently presented at the ...
... they closely matched the real personalities of the profile ... the notion that Internet users favor idealized virtual identities, ... networking sites such as Facebook create profiles that stick ... networks may be more interested in fostering real communication ...
... ... ... ... ...
Cached Medicine News:Health News:Drug Improved Survival in Mice With Cystic Fibrosis 2Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 2Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 3Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 4Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 5Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 6Health News:CapSite Announces Release of the 2010 U.S. Ambulatory EHR Study 2Health News:Facebook Profiles Don't Stretch the Truth 2Health News:Facebook Profiles Don't Stretch the Truth 3Health News:Facebook Profiles Don't Stretch the Truth 4Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 2Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 3Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 4Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 5Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 6Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 7Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 8Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 9Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 10Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 11Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 12Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 13Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 14Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 15Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 16
Verte-Span is the latest advancement in vertebral body replacement technology. This device allows surgeons to reconstruct and stabilize certain types of anterior column defects in the spine....
... is indicated for use in the thoracolumbar spine ... or excised for the treatment of tumors, to ... neural tissues, and to restore the height of ... also indicated for treating fractures of the thoracic ...
... Ocelot stackable cage system provides anterior ... or total vertebrectomies from T1 to L5. ... Peek Carbon fiber polymer cages that are ... patient needs. The Peek Carbon fiber reinforced ...
... Ocelot stackable cage system provides anterior ... or total vertebrectomies from T1 to L5. ... Peek Carbon fiber polymer cages that are ... patient needs. The Peek Carbon fiber reinforced ...
Medicine Products: